Showing 3891-3900 of 9876 results for "".
- Aveeno Names Winners of the 2022 Skin Health Accelerator Startup Pitch Competitionhttps://practicaldermatology.com/news/aveeno-names-winners-of-the-2022-skin-health-accelerator-startup-pitch-competition/2461263/Aveeno awarded the winners of the second installment of the brand’s
- Data Demonstrate Safety, Efficacy of Dupilumab for AD in Patients as Young as Six Monthshttps://practicaldermatology.com/news/data-demonstrate-safety-efficacy-of-dupilumab-for-ad-in-patients-as-young-as-six-months/2461005/Data demonstrating the safety and efficacy of Sanofi and Regeneron’s
- Burt's Bees Sensitive Skincare Line Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/burts-bees-sensitive-skincare-line-awarded-national-eczema-association-seal-of-acceptance/2457892/The National Eczema Society (NEA) has awarded Burt's Bees' Sensitive skin care line the NEA's Seal of Acceptance, which maintains rigorous standards for approval. The Sensitive skin care line includes Burt's Bees Sensitive Facial Cleanser, Burt's Bees Sensitive Eye Cream, Burt
- Alastin Skincare's INhance Post-Injection Serum Reduces Bruisinghttps://practicaldermatology.com/news/alastin-skincares-inhance-post-injection-serum-reduces-bruising/2460419/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in Dermatology. In
- HydraFacial Company Partners With Alastin Skincarehttps://practicaldermatology.com/news/hydrafacial-company-partners-with-alastin-skincare/2459931/Alastin Skincare’s TriHex-Pro Skin Booster Serum is now available at HydraFacial providers across the United States. The key ingredient in the TriHex-Pro Skin Booster Serum is Alastin's proprieta
- Promising and Consistent Topline Results Seen in Phase 3 Trial of Roflumilast in ADhttps://practicaldermatology.com/news/promising-and-consistent-topline-results-seen-in-phase-3-trial-of-roflumilast-in-ad/2461466/Arcutis Biotherapeutics, Inc.’s roflumilast met the key primary and secondary endpoints in the INT
- ICYMI: Dispatches from The Skin of Color Society’s 18th Annual Scientific Symposiumhttps://practicaldermatology.com/news/icymi-dispatches-from-the-skin-of-color-societys-18th-annual-scientific-symposium/2461157/The Skin of Color Society’s 18th Annual Scientific Symposium wowed the crowd during the American Academ
- FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scopehttps://practicaldermatology.com/news/fda-green-lights-casios-dz-d100-dermocamera-and-the-dz-s50-scope/2461076/The U.S. Food and Drug Administration (FDA) has cleared Casio’s
- Hologic's Cynosure Division Launches TempSure Surgical RF Technology in North Americahttps://practicaldermatology.com/news/hologics-cynosure-division-launches-tempsure-surgical-rf-technology-in-north-america/2457541/Hologic, Inc.’s Cynosure division is launching the U.S. Food and Drug Administration (FDA)-cleared
- WDS Offers Skin Cancer Screeningshttps://practicaldermatology.com/news/wds-to-offer-skin-cancer-screenings/2458077/The Women’s Dermatologic Society (WDS) Play Safe in the Sun Program is slated to par